TNFerade: Interim Phase II data

Interim data from a dose-escalation, U.S. Phase II trial in 24 patients showed that TNFerade in combination

Read the full 170 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE